With the development of a highly sensitive immunoassay such as the Simoa® assay, the detection of NfL at femtomolar levels in the serum of MS patients is made possible and may assist with the clinical interpretation of MS progression [171,172,173], negating the need to extract NfL from the CSF in these patients. The gene discussed is NEFL; the disease is myeloid sarcoma.